Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
PLoS One ; 9(6): e98685, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24927156

RESUMO

Recombinant influenza viruses are promising viral platforms to be used as antigen delivery vectors. To this aim, one of the most promising approaches consists of generating recombinant viruses harboring partially truncated neuraminidase (NA) segments. To date, all studies have pointed to safety and usefulness of this viral platform. However, some aspects of the inflammatory and immune responses triggered by those recombinant viruses and their safety to immunocompromised hosts remained to be elucidated. In the present study, we generated a recombinant influenza virus harboring a truncated NA segment (vNA-Δ) and evaluated the innate and inflammatory responses and the safety of this recombinant virus in wild type or knock-out (KO) mice with impaired innate (Myd88 -/-) or acquired (RAG -/-) immune responses. Infection using truncated neuraminidase influenza virus was harmless regarding lung and systemic inflammatory response in wild type mice and was highly attenuated in KO mice. We also demonstrated that vNA-Δ infection does not induce unbalanced cytokine production that strongly contributes to lung damage in infected mice. In addition, the recombinant influenza virus was able to trigger both local and systemic virus-specific humoral and CD8+ T cellular immune responses which protected immunized mice against the challenge with a lethal dose of homologous A/PR8/34 influenza virus. Taken together, our findings suggest and reinforce the safety of using NA deleted influenza viruses as antigen delivery vectors against human or veterinary pathogens.


Assuntos
Proteínas de Homeodomínio/genética , Vírus da Influenza A/enzimologia , Vacinas contra Influenza/genética , Fator 88 de Diferenciação Mieloide/genética , Neuraminidase/genética , Infecções por Orthomyxoviridae/imunologia , Proteínas Virais/genética , Animais , Cães , Técnicas de Inativação de Genes , Imunidade Celular/imunologia , Vírus da Influenza A/genética , Vacinas contra Influenza/imunologia , Células Madin Darby de Rim Canino , Camundongos , Camundongos Endogâmicos C57BL , Neuraminidase/imunologia , Vacinas Sintéticas/genética , Vacinas Sintéticas/imunologia , Proteínas Virais/imunologia
2.
Toxicon ; 85: 5-16, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-24751366

RESUMO

Crotoxin (Crtx), the main toxin in the venom of Crotalus durissus terrificus snake, is a heterodimer with a basic subunit, CB, and an acidic subunit, CA. CB is a phospholipase A2 that depends on CA to specifically bind to the cell membrane. This toxin acts in the central nervous system (CNS) causing chronic seizure effects and other cytotoxic effects. Here, we report its action on glutamate release in rat cerebral cortex synaptosomes. Aiming at a better understanding of the mechanism of action of Crtx, calcium channel blockers were used and internalization studies were performed in cerebellar granule neurons. Our results show that Crtx induces calcium-dependent glutamate release via N and P/Q calcium channels. In addition, the CB subunit of Crtx is shown to be internalized. This internalization does not depend on the presence of CA subunit neither on the PLA2 activity of CB. A correlation between CB internalization and glutamate release remains to be established.


Assuntos
Agonistas dos Canais de Cálcio/farmacologia , Canais de Cálcio Tipo N/metabolismo , Córtex Cerebral/efeitos dos fármacos , Venenos de Crotalídeos/química , Crotalus , Crotoxina/farmacologia , Sinaptossomos/efeitos dos fármacos , Animais , Agonistas dos Canais de Cálcio/metabolismo , Bloqueadores dos Canais de Cálcio/farmacologia , Canais de Cálcio Tipo N/química , Sinalização do Cálcio/efeitos dos fármacos , Células Cultivadas , Córtex Cerebral/metabolismo , Venenos de Crotalídeos/enzimologia , Crotoxina/antagonistas & inibidores , Crotoxina/metabolismo , Ácido Glutâmico/metabolismo , Fosfolipases A2 do Grupo II/antagonistas & inibidores , Fosfolipases A2 do Grupo II/metabolismo , Fosfolipases A2 do Grupo II/farmacologia , Masculino , Proteínas do Tecido Nervoso/agonistas , Proteínas do Tecido Nervoso/antagonistas & inibidores , Proteínas do Tecido Nervoso/metabolismo , Neurônios/efeitos dos fármacos , Neurônios/metabolismo , Neurotoxinas/antagonistas & inibidores , Neurotoxinas/metabolismo , Neurotoxinas/farmacologia , Subunidades Proteicas/antagonistas & inibidores , Subunidades Proteicas/metabolismo , Subunidades Proteicas/farmacologia , Transporte Proteico/efeitos dos fármacos , Ratos Wistar , Proteínas de Répteis/antagonistas & inibidores , Proteínas de Répteis/metabolismo , Proteínas de Répteis/farmacologia , Transmissão Sináptica/efeitos dos fármacos , Sinaptossomos/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA